Merck, Inc.
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
- Conditions
- Interventions
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 531
- Registration Number
- NCT04956692
- Locations
- 🇫🇷
Institut Regional du Cancer de Montpellier - ICM ( Site 1003), Montpellier, Herault, France
🇺🇸St. Bernards Medical Center ( Site 0103), Jonesboro, Arkansas, United States
🇺🇸West Virginia University ( Site 0056), Morgantown, West Virginia, United States
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 862
- Registration Number
- NCT04949256
- Locations
- 🇨🇷
PROCLINICAL Pharma ( Site 0904), San José, San Jose, Costa Rica
🇨🇳Shanxi Provincial Cancer Hospital ( Site 8019), Taiyuan, Shanxi, China
🇨🇳West China Hospital of Sichuan University ( Site 8048), Chengdu, Sichuan, China
A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)
- Conditions
- Interventions
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 145
- Registration Number
- NCT04944992
- Locations
- 🇦🇷
CIPREC-Laboratorio ( Site 0104), Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
🇮🇱Carmel Hospital-Liver Unit ( Site 0705), Haifa, Israel
🇮🇱Rabin Medical Center ( Site 0701), Petah-Tikva, Israel
Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
- Conditions
- Interventions
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2441
- Registration Number
- NCT04939428
- Locations
- 🇺🇸
University of Missouri Hospital ( Site 2486), Columbia, Missouri, United States
🇺🇸ECU Adult Specialty Care ( Site 2415), Greenville, North Carolina, United States
🇺🇸ASCADA Research, LLC ( Site 2516), Fullerton, California, United States
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
- First Posted Date
- 2021-06-24
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 110
- Registration Number
- NCT04938817
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center ( Site 0152), Gilbert, Arizona, United States
🇺🇸Northside Hospital-Northside Hospital Oncology Network ( Site 0156), Atlanta, Georgia, United States
🇺🇸Parkview Research Center at Parkview Regional Medical Center ( Site 0180), Fort Wayne, Indiana, United States
Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)
- Conditions
- Interventions
- First Posted Date
- 2021-06-24
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1000
- Registration Number
- NCT04938830
- Locations
- 🇺🇸
DHR Health Institute for Research and Development ( Site 0029), Edinburg, Texas, United States
🇺🇸NYU Langone Hospital - Long Island-Pediatrics ( Site 0028), Mineola, New York, United States
🇺🇸Miller Children's & Women's Hospital Long Beach ( Site 0001), Long Beach, California, United States
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension
- Conditions
- Interventions
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 186
- Registration Number
- NCT04934722
- Locations
- 🇨🇳
Zhejiang Provincial People's Hospital ( Site 0809), Hangzhou, Zhejiang, China
🇨🇳The First Affiliated Hospital of Wenzhou Medical University ( Site 0834), Wenzhou, Zhejiang, China
🇨🇳The first affiliated Hospital of Xi an Jiaotong University ( Site # 0812), XI An, Shanxi, China
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)
- Conditions
- Interventions
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT04924101
- Locations
- 🇺🇸
UPMC Hillman Cancer Center ( Site 0127), Pittsburgh, Pennsylvania, United States
🇺🇸MFSMC-HJWCI-Oncology Research ( Site 0128), Baltimore, Maryland, United States
🇺🇸Cleveland Clinic-Taussig Cancer Center ( Site 0116), Cleveland, Ohio, United States
A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)
- Conditions
- Interventions
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 57
- Registration Number
- NCT04924114
- Locations
- 🇺🇸
IHS. Health, LLC ( Site 0104), Kissimmee, Florida, United States
🇺🇸Pinnacle Clinical Research ( Site 0103), San Antonio, Texas, United States
🇩🇪Charite Research Organisation GmbH ( Site 0201), Berlin, Germany
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 322
- Registration Number
- NCT04924075
- Locations
- 🇳🇴
Oslo Universitetssykehus Radiumhospitalet ( Site 2400), Oslo, Norway
🇺🇸Cedars-Sinai Medical Center ( Site 0110), Los Angeles, California, United States
🇺🇸University of Iowa ( Site 0104), Iowa City, Iowa, United States